share_log

康寧傑瑞製藥-B：自願公告 - 於2024年AACR年會呈列的JSKN003用於治療HER2表達晚期實體瘤的I期臨床研究的最新結果

ALPHAMAB-B: VOLUNTARY ANNOUNCEMENT - UPDATES ON RESULTS OF A PHASE I CLINICAL TRIAL OF JSKN003 FOR THE TREATMENT OF HER2-EXPRESSING ADVANCED SOLID TUMORS FOR PRESENTATION AT 2024 AACR ANNUAL MEETING

香港交易所 ·  Apr 10 06:05
Summary by Futu AI
康寧傑瑞生物製藥（ALPHAMAB ONCOLOGY）於2024年4月5日至10日的美國癌症研究協會年會（AACR）上，發表了其藥物JSKN003用於治療HER2表達晚期實體瘤的I期臨床研究最新結果。該研究顯示，JSKN003在晚期╱轉移性實體瘤患者中具有良好的耐受性和安全性，並展現出初步的抗腫瘤活性。研究結果包括32例患者的數據，其中多數患者接受過至少三線系統性治療。療效方面，客觀緩解率（ORR）和疾病控制率（DCR）分別為56.3%和90.6%。藥物的血液毒性和間質性肺疾病（ILD）的發生率低。JSKN003是一種靶向HER2的抗體偶聯藥物（ADC），目前在澳大利亞和中國進行臨床試驗，並推進中國III期臨床試驗。康寧傑瑞生物製藥是一家專注於腫瘤治療的生物製藥公司，擁有多個處於不同研發階段的產品。
康寧傑瑞生物製藥（ALPHAMAB ONCOLOGY）於2024年4月5日至10日的美國癌症研究協會年會（AACR）上，發表了其藥物JSKN003用於治療HER2表達晚期實體瘤的I期臨床研究最新結果。該研究顯示，JSKN003在晚期╱轉移性實體瘤患者中具有良好的耐受性和安全性，並展現出初步的抗腫瘤活性。研究結果包括32例患者的數據，其中多數患者接受過至少三線系統性治療。療效方面，客觀緩解率（ORR）和疾病控制率（DCR）分別為56.3%和90.6%。藥物的血液毒性和間質性肺疾病（ILD）的發生率低。JSKN003是一種靶向HER2的抗體偶聯藥物（ADC），目前在澳大利亞和中國進行臨床試驗，並推進中國III期臨床試驗。康寧傑瑞生物製藥是一家專注於腫瘤治療的生物製藥公司，擁有多個處於不同研發階段的產品。
CORNING JERRY BIOPHARMACEUTICALS (ALPHAMAB ONCOLOGY) ANNOUNCED THE LATEST RESULTS OF A PHASE I CLINICAL TRIAL OF ITS DRUG JSKN003 FOR THE TREATMENT OF HER2-EXPRESSED LATE-STAGE SOLID TUMORS ON APRIL 5-10, 2024. The study showed that JSKN003 had good tolerability and safety in patients with late-stage and metastatic solid tumors, and showed initial antitumor activity. The results include data from 32 patients, most of whom received at least three-line systemic therapy. In terms of efficacy, the objective mitigation rate (ORR) and disease control rate (DCR) are 56.3% and 90.6%, respectively. The drug has a low rate of hematotoxicity and interstitial lung disease (ILD). JSKN003 IS AN ANTIBODY DUPLICATED DRUG (ADC) TARGETING HER2 CURRENTLY IN CLINICAL TRIALS IN AUSTRALIA AND CHINA, AND ADVANCING A PHASE III CLINICAL TRIAL IN CHINA. Corning Jerry Biopharmaceuticals is a biopharmaceutical company focused on the treatment of tumors with several products in different stages of development.
CORNING JERRY BIOPHARMACEUTICALS (ALPHAMAB ONCOLOGY) ANNOUNCED THE LATEST RESULTS OF A PHASE I CLINICAL TRIAL OF ITS DRUG JSKN003 FOR THE TREATMENT OF HER2-EXPRESSED LATE-STAGE SOLID TUMORS ON APRIL 5-10, 2024. The study showed that JSKN003 had good tolerability and safety in patients with late-stage and metastatic solid tumors, and showed initial antitumor activity. The results include data from 32 patients, most of whom received at least three-line systemic therapy. In terms of efficacy, the objective mitigation rate (ORR) and disease control rate (DCR) are 56.3% and 90.6%, respectively. The drug has a low rate of hematotoxicity and interstitial lung disease (ILD). JSKN003 IS AN ANTIBODY DUPLICATED DRUG (ADC) TARGETING HER2 CURRENTLY IN CLINICAL TRIALS IN AUSTRALIA AND CHINA, AND ADVANCING A PHASE III CLINICAL TRIAL IN CHINA. Corning Jerry Biopharmaceuticals is a biopharmaceutical company focused on the treatment of tumors with several products in different stages of development.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.